Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nateglinide/Metformin Combined Tablet vs Separate Tablets
NCT02088918Phase 1Completed
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Oct 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nateglinide and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoints: Area Under the Curve to the last quantifiable concentration and Maximum Plasma Concentration. Started Oct 2012; status: completed.
02
Drugs
nateglinidemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02088918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088918.